Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 0.85 |
| ▸ | SLC6A3 | Q01959 | 17/20 | 0.85 |
| ▸ | SLC6A2 | P23975 | 16/20 | 0.85 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3466791 | 1.00 | SLC6A4 (0.85) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| Hydrochloric Acid SCHEMBL6543325 | 0.99 | SLC6A4 (0.83) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL14415545 | 0.92 | SLC6A4 (0.71) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL1981733 | 0.92 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL3466313 | 0.92 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL1981732 | 0.92 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| Fumaric Acid SCHEMBL6139595 | 0.91 | SLC6A4 (0.71) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| Fumaric Acid SCHEMBL6139599 | 0.91 | SLC6A4 (0.71) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL8458076 | 0.88 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6 | |
| SCHEMBL3466142 | 0.87 | SLC6A4 (0.72) | SLC6A4SLC6A3SLC6A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0888304-B1 | SUBSTITUTED 3-ARYL-3-CARBOXYALKYL GLUTARAMIDES, METHOD FOR PREPARING SAME BY 4-ARYLO-4-CYANOHEPTANE DICARBOXYLIC ACID CYCLISATION, AND USE THEREOF FOR PREPARING 3-ARYL-3-HYDROXYALKYLPIPERIDINES | SANOFI SYNTHELABO (FR) | 2001-10-04 | — | — | EP | claimed |
| EP-0888304-A1 | SUBSTITUTED 3-ARYL-3-CARBOXYALKYL GLUTARAMIDES, METHOD FOR PREPARING SAME BY 4-ARYLO-4-CYANOHEPTANE DICARBOXYLIC ACID CYCLISATION, AND USE THEREOF FOR PREPARING 3-ARYL-3-HYDROXYALKYLPIPERIDINES | SANOFI (FR) | 1999-01-07 | — | — | EP | claimed |
| WO-1997032852-A1 | SUBSTITUTED 3-ARYL-3-CARBOXYALKYL GLUTARAMIDES, METHOD FOR PREPARING SAME BY 4-ARYLO-4-CYANOHEPTANE DICARBOXYLIC ACID CYCLISATION, AND USE THEREOF FOR PREPARING 3-ARYL-3-HYDROXYALKYLPIPERIDINES | SANOFI (FR) | 1997-09-12 | — | — | WO | claimed |
| WO-2023278843-A2 | SOLID FORMS OF OSANETANT | ACER THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| EP-1140842-B1 | ALKYL ESTERS OF 3-(3,4-DIHALOGENOPHENYL)-2,6-DIOXOPIPERIDINE-3-PROPIONIC ACID USEFUL AS INTERMEDIATES | SANOFI AVENTIS (FR) | 2005-11-02 | — | — | EP | disclosed |
| US-6946269-B2 | Alkyl esters of 3-(3,4-dihalophenyl)-2,6-dioxopiperidine-3-propionic acid of use as intermediates | SANOFI-AVENTIS (FR) | 2005-09-20 | — | — | US | disclosed |
| US-20040110796-A1 | Alkyl esters of 3- (3,4-dihalophenyl) -2, 6 -di -oxopiperidine-3 -propionic acid of use as intermediates | SANOFI-AVENTIS (FR) | 2004-06-10 | — | — | US | disclosed |
| US-6686182-B2 | ANTAGONISTS OF NATURAL KILLER CELL-3 RECEPTORS | SANOFI-SYNTHELABO (FR) | 2004-02-03 | — | — | US | disclosed |
| EP-1019373-B1 | 1-ACYL-3-PHENYL-3-(3-PIPERIDINOPROPYL)PIPERIDINE DERIVATIVES AS HUMAN NK3 RECEPTOR SELECTIVE ANTAGONISTS | SANOFI SYNTHELABO (FR) | 2003-11-12 | — | — | EP | disclosed |
| US-6602886-B2 | 3-alkyl-3-phenyl-piperidines | WARNER-LAMBERT COMPANY | 2003-08-05 | — | — | US | disclosed |
| US-20030073838-A1 | 3-alkyl-3-phenyl-piperidines | CHEN MICHAEL HUAI GU (US) | 2003-04-17 | — | — | US | disclosed |
| EP-1019373-A1 | NOVEL HUMAN NK 3? RECEPTOR-SELECTIVE ANTAGONIST COMPOUNDS, METHOD FOR OBTAINING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 2000-07-19 | — | — | EP | disclosed |
| US-6040316-A | TACHYKININ ANTAGONISTS TREATING PAIN, DEPRESSION, ANXIETY, PANIC, SCHIZOPHRENIA, NEURALGIA, ADDICTION DISORDERS, INFLAMMATORY DISEASES, GASTROINTESTINAL DISORDERS, VASCULAR DISORDERS, AND NEUROPATHOLOGICAL DISORDERS | WARNER-LAMBERT COMPANY (US) | 2000-03-21 | — | — | US | disclosed |
| US-6008360-A | Substituted 3-aryl-3-carboxyalkyl glutaramides, method for preparing same by 4-arylo-4-cyanoheptane dicarboxylic acid cyclisation, and use thereof for preparing 3-aryl-3-hydroxyalkylpiperidines | SANOFI-SYNTHELABO (FR) | 1999-12-28 | — | — | US | disclosed |
| EP-0915849-A2 | PROCESS FOR THE PREPARATION OF 3,3-DISUBSTITUTED PIPERIDINES | Smithkline Beecham S.p.A. (IT) | 1999-05-19 | — | — | EP | disclosed |
| EP-0888304-A1 | SUBSTITUTED 3-ARYL-3-CARBOXYALKYL GLUTARAMIDES, METHOD FOR PREPARING SAME BY 4-ARYLO-4-CYANOHEPTANE DICARBOXYLIC ACID CYCLISATION, AND USE THEREOF FOR PREPARING 3-ARYL-3-HYDROXYALKYLPIPERIDINES | SANOFI (FR) | 1999-01-07 | — | — | EP | disclosed |
| WO-1998005640-A2 | PROCESS FOR THE PREPARATION OF 3,3-DISUBSTITUTED PIPERIDINES | SMITHKLINE BEECHAM S.P.A. (IT) | 1998-02-12 | — | — | WO | disclosed |
| WO-1997032852-A1 | SUBSTITUTED 3-ARYL-3-CARBOXYALKYL GLUTARAMIDES, METHOD FOR PREPARING SAME BY 4-ARYLO-4-CYANOHEPTANE DICARBOXYLIC ACID CYCLISATION, AND USE THEREOF FOR PREPARING 3-ARYL-3-HYDROXYALKYLPIPERIDINES | SANOFI (FR) | 1997-09-12 | — | — | WO | disclosed |
| WO-1997010211-A1 | NOVEL HUMAN NK3 RECEPTOR-SELECTIVE ANTAGONIST COMPOUNDS, METHOD FOR OBTAINING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI (FR) | 1997-03-20 | — | — | WO | disclosed |
| EP-0673928-A1 | Novel N-(3,4-dichlorophenyl-propyl)-piperidine derivatives as selective human NK3-receptor antagonists | SANOFI (FR) | 1995-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110796-A1 | Alkyl esters of 3- (3,4-dihalophenyl) -2, 6 -di -oxopiperidine-3 -propionic acid of use as intermediates | NAPEPLD, FFAR3, APEH | SLC6A4 1230/4885SLC6A3 442/4885SLC6A2 1278/4885 |
| US-20030073838-A1 | 3-alkyl-3-phenyl-piperidines | TAC3, KCNK3, ACKR3 | SLC6A4 89/4885SLC6A3 16/4885SLC6A2 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.